Major strength is demonstration of the importance of glucose metabolism for the successful treatment with IMD‐3 using a therapy‐resistant in vitro cancer model, leading to emergence of possible therapy‐relevant predictive markers, such as GLUT‐1. This evidence concerns the gene SLC2A1 and cancer.